NEUCA S.A. (WSE:NEU)
Poland
· Delayed Price · Currency is PLN 818.00
-5.00 (-0.61%)
At close: Dec 5, 2025
NEUCA Revenue
NEUCA had revenue of 3.49B PLN in the quarter ending September 30, 2025, with 9.53% growth. This brings the company's revenue in the last twelve months to 13.34B, up 8.11% year-over-year. In the year 2024, NEUCA had annual revenue of 12.61B with 6.76% growth.
Revenue (ttm)
13.34B
Revenue Growth
+8.11%
P/S Ratio
0.27
Revenue / Employee
3.00M
Employees
4,445
Market Cap
3.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12.61B | 799.12M | 6.76% |
| Dec 31, 2023 | 11.81B | 580.45M | 5.17% |
| Dec 31, 2022 | 11.23B | 1.37B | 13.87% |
| Dec 31, 2021 | 9.86B | 619.37M | 6.70% |
| Dec 31, 2020 | 9.24B | 972.52M | 11.76% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Diagnostyka | 2.30B |
| Synektik Spólka Akcyjna | 623.20M |
| Voxel | 568.83M |
| Celon Pharma | 225.60M |
| Selvita | 373.90M |
| Ryvu Therapeutics | 90.41M |
| Centrum Medyczne ENEL-MED | 820.59M |
| Scope Fluidics | 718.00K |